Continuation, Resumption, and Withdrawal Rates of CGRP-mAb Treatment for Migraine Under Real-World Clinical Conditions in Which Patients Are Free to Choose Own Treatment

Background/Objectives: Anti-calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) are effective injectable medications for the treatment of migraine. This study aimed to evaluate continuation, resumption, and withdrawal rates of CGRP-mAb treatment under real-world clinical conditions. Me...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Takafumi Tanei, Satoshi Yamashita, Satoshi Maesawa, Yusuke Nishimura, Tomotaka Ishizaki, Yoshitaka Nagashima, Takahiro Suzuki, Hajime Hamasaki, Shun Yamamoto, Toshihiko Wakabayashi, Ryuta Saito
Format:	Artigo
Język:	Inglês
Wydane:	MDPI AG 2025-12-01
Seria:	Neurology International
Hasła przedmiotowe:	CGRP continuation migraine resumption withdrawal
Dostęp online:	https://www.mdpi.com/2035-8377/18/1/3
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!